Remotely Delivered, Culturally Tailored Weight Loss Interventions Among Latina Breast Cancer Survivors

Description

This clinical trial evaluates a remotely delivered, culturally tailored weight loss interventions in Latina breast cancer (BC) survivors. Cancer is the leading cause of death among Latinos, and among Latinas, BC is the leading cause of cancer death. An estimated 80% of Latinas in the United States have overweight/obesity, which is associated with poorer BC outcomes. However, few, if any, effective interventions exist to promote and maintain weight loss in Latina BC survivors. The development of an adaptive program that provides survivors the support they need, as opposed to what is typically available, is essential to reducing persistent inequities in cancer survivorship.

Conditions

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8

Talk to us

Study Overview

On this page

Study Details

Study overview

This clinical trial evaluates a remotely delivered, culturally tailored weight loss interventions in Latina breast cancer (BC) survivors. Cancer is the leading cause of death among Latinos, and among Latinas, BC is the leading cause of cancer death. An estimated 80% of Latinas in the United States have overweight/obesity, which is associated with poorer BC outcomes. However, few, if any, effective interventions exist to promote and maintain weight loss in Latina BC survivors. The development of an adaptive program that provides survivors the support they need, as opposed to what is typically available, is essential to reducing persistent inequities in cancer survivorship.

Using a SMART Design to Evaluate Remotely Delivered, Culturally Tailored Weight Loss Interventions Among Latina Breast Cancer Survivors

Remotely Delivered, Culturally Tailored Weight Loss Interventions Among Latina Breast Cancer Survivors

Condition
Anatomic Stage I Breast Cancer AJCC v8
Intervention / Treatment

-

Contacts and Locations

Seattle

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States, 98109

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Biologically female
  • * Age \>= 18 years
  • * Self-identifies Hispanic/Latina
  • * Fluent in Spanish and/or English
  • * Previously diagnosis of stage I-III BC within the past 5 years
  • * No evidence of recurrent or metastatic disease
  • * \> 60 days post treatment (current endocrine therapy allowed)
  • * Body mass index (BMI) \>= 30 kg/m\^2 initially assessed via self-reported height and weight and confirmed prior to randomization via a tape measure and WiFi-enabled scale
  • * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • * Physician written clearance for participation in a 12 month weight loss program
  • * Willingness to participate in all study activities
  • * Access to phone for study contacts
  • * Access to internet and smartphone, tablet, or computer to participate in the online program and to be able to sync study WiFi devices
  • * Lives within grocery delivery range for online delivery service
  • * Successful completion of at-home baseline assessments prior to randomization
  • * Body mass index (BMI) \< 30 kg/m\^2
  • * Active smoker
  • * Diabetic with use of insulin or other hypoglycemic medication
  • * Major comorbidities or physical limitations that would preclude from healthy weight loss, reducing energy intake or engaging in PA
  • * Pregnant, breastfeeding, or planning to become pregnant during the study period
  • * Use of exogenous hormones for gender affirmation

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Fred Hutchinson Cancer Center,

Heather Greenlee, PRINCIPAL_INVESTIGATOR, Fred Hutch/University of Washington Cancer Consortium

Study Record Dates

2028-03-01